Inventiva Logo

Inventiva

IVA | PA

Overview

Corporate Details

ISIN(s):
FR0013233012 (+2 more)
LEI:
969500I9Y690B3FZW590
Country:
France
Address:
50 RUE DE DIJON, 21121 DAIX
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Inventiva is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies for diseases with significant unmet medical needs. The company's research and development primarily target fibrosis, lysosomal storage disorders, and oncology. Its lead drug candidate, lanifibranor, is in a pivotal Phase III trial for the treatment of Non-Alcoholic Steatohepatitis (NASH) and has received Breakthrough Therapy Designation from the FDA. Another clinical candidate, odiparcil, targets Mucopolysaccharidosis (MPS). Inventiva's pipeline is supported by a proprietary discovery platform, which includes an extensive library of approximately 240,000 molecules, a wholly-owned research facility, and expertise in compounds that modulate nuclear receptors and transcription factors.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Inventiva. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-19 15:35
Major Shareholding Notification
Franchissement de seuil
French 116.8 KB
2025-08-19 15:32
Major Shareholding Notification
Franchissement de seuil
French 116.7 KB
2025-08-19 15:19
Major Shareholding Notification
Franchissement de seuil
French 116.1 KB
2025-08-12 15:57
Major Shareholding Notification
Franchissement de seuil
French 113.9 KB
2025-08-12 15:52
Major Shareholding Notification
Franchissements de seuil
French 121.6 KB
2025-08-11 15:14
Major Shareholding Notification
Franchissement de seuil
French 121.9 KB
2025-06-17 17:02
Major Shareholding Notification
Franchissement de seuils
French 113.4 KB
2025-06-10 22:00
Board/Management Information
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Di…
English 243.0 KB
2025-05-27 22:00
Regulatory News Service
Inventiva Participera à la « Jefferies Global Healthcare Conference » et à la «…
French 217.7 KB
2025-05-27 22:00
Regulatory News Service
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference…
English 160.0 KB
2025-05-23 08:30
Earnings Release
Inventiva reports 2025 First Quarter Financial Information¹
English 299.4 KB
2025-05-23 08:30
Earnings Release
Inventiva publie ses informations financières¹ du 1er trimestre 2025
French 335.4 KB
2025-05-23 08:00
Declaration of Voting Results & Voting Rights Announcements
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2…
English 348.3 KB
2025-05-23 08:00
Post-Annual General Meeting Information
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 2…
French 347.8 KB
2025-05-22 14:00
Transaction in Own Shares
Descriptif du Programme de Rachat d’Actions Pouvant Être Mis en Œuvre dans le C…
French 275.8 KB

Automate Your Workflow. Get a real-time feed of all Inventiva filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Inventiva via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-05 N/A Other Buy 10,000 N/A
2023-12-08 N/A Other Buy 15,000 N/A

Peer Companies

Company Country Ticker View
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A biopharma firm that developed cannabinoid pain therapies, now in administration and ceased trading.
United Kingdom OCTHF
Oxurion NV Logo
Biopharmaceutical company providing Contract Research Organization (CRO) services to life sciences.
Belgium OXUR
PCI Biotech Holding Logo
Develops light-activated drug delivery for cancer, dermatology, and gene therapy manufacturing.
Norway PCIB
Pentixapharm Holding AG Logo
Develops first-in-class radiopharmaceuticals for cancer diagnosis and therapy (theranostics).
Germany PTP
PharmaLundensis AB Logo
Develops drugs to bind and excrete heavy metals for treating COPD, bronchitis, and depression.
Sweden PHAL
Pharnext Logo France ALPHA
Pherecydes Pharma Logo
Developing precision phage therapies for antibiotic-resistant bacterial infections.
France ALPHE
Philogen Logo
Develops antibody-based biopharmaceuticals for targeted cancer and inflammation treatment.
Italy PHIL
PHYSIOMICS PLC Logo
De-risks oncology drug development for pharma/biotech using modeling and simulation.
United Kingdom PYC
PILA PHARMA AB Logo
Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.
Sweden PILA